NCT03477513Completed
Personalized Radiation Therapy for GBM
Personalized Treatment of Glioblastoma Via Image-Guided Predictive Modeling of Recurrence: A Single-Arm, Single Institutional Pilot Prospective Study of Dose-Escalated Radiation Therapy
Source: ClinicalTrials.gov · Last updated 8 Jul 2026
Brief summary (registry, in English)
The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival. Toxicity, patterns of recurrence, and overall median survival will be measured as secondary endpoints. Adverse events will be monitored.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 23 (actual)
- First submitted
- 20 Mar 2018
- Start date
- 1 Mar 2018
- Primary completion date
- 1 Apr 2026
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Glioblastoma
- NCT number
- NCT03477513
What you commit to
- Study type: Interventional
- Participants enrolled: 23
- From 1 Mar 2018 to the primary completion date, 1 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Placement of Gliadel wafers
Other illness
- Active treatment of another malignancy
Other
- Participation in another investigational trial
Who the study is looking for
- Patients with biopsy-proven WHO Grade IV glioblastoma, after gross-total or near-total resection, who are undergoing definitive chemoradiation as part of their treatment regimen
- Age 18 or older
- Ability to give signed informed consent
- Karnofsky Performance Status (KPS) at least 70
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Abramson Cancer Center of the University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
Related publications
- Personalized machine learning-guided radiation dose escalation in newly diagnosed glioblastoma: prospective pilot study.Nat Commun · 2026 · PMID 42129213
This page is information, not medical advice. Discuss any trial with your doctor.